Novartis-Alnylam deal produces revenue for Isis

09/13/2005 | Yahoo!

The recently announced Novartis partnership with Alnylam for the development of RNA interference drugs is expected to produce nearly $4 million for California-based Isis Pharmaceuticals. Isis said it is entitled to a share of the Novartis upfront payments to Alnylam as a result of the technology Isis had licensed to Alnylam.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI